PI3K‐α/mTOR/BRD4 inhibitor alone or in combination with other anti‐virals blocks replication of SARS‐CoV‐2 and its variants of concern including Delta and Omicron

Abstract excerpt

We demonstrated that SF2523, a dual small molecule inhibitor of PI3K-α/mTOR/BRD4 pathways, can inhibit the replication of SARS-CoV-2 and its emerging variants of concern (VOCs), including Delta and Omicron. Further, we also found that SF2523 acts synergistically with remdesivir (RDV) and MU-UNMC-2 (a small molecule entry inhibitor of SARS-CoV-2).1 The ongoing COVID-19 pandemic due to the emergence of a novel...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to COVID-19 Clinical Research Studies
• Share to PARP inhibition in cancer therapy
• Share to SARS-CoV-2 and COVID-19 Research